Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Becton Dickinson and Co    BDX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Becton Dickinson's 1st-Quarter Earnings Surge; Raises Year-View

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/05/2013 | 12:50pm CEST
   By Saabira Chaudhuri 
 

Becton Dickinson & Co.'s (>> Becton, Dickinson and Co.) fiscal first-quarter earnings more than doubled as the medical device maker recorded revenue growth across all its segments, while margins also widened.

For the current year, Becton raised the bottom end of its revenue guidance, now expecting foreign currency neutral revenue growth starting at 4% versus its prior view starting at 3.5%. It now expects per-share earnings from continuing operations between $5.69 and $5.72, up from its prior view of earnings between $5.58 and $5.64.

The maker of products like surgical blades and test kits last spring struck a deal to sell the bulk of its lab-products business to Corning Inc. (>> Corning Incorporated) for $730 million in cash. Analysts who follow the company noted the sale stripped Becton Dickinson of a cash cow yet also gave it the freedom to focus on businesses with higher growth potential.

Ahead of the company's earnings announcement, analysts at Mizuho Securities downgraded Becton's ratings, noting that the company's life science research business--which makes up about 15% of sales--has been a drag on results for the past year, adding that they see no significant catalysts for the business in the near-term, as the academic market continues to be sluggish.

Still, Chief Executive Vincent A. Forlenza on Tuesday said the company is "starting to see notable results," adding that Becton is "growing revenues across our three segments, driving margin expansion and delivering a higher quality of earnings."

For the quarter ended Dec. 31, Becton Dickinson reported a profit of $625.4 million, or $3.13 a share, compared with $263 million, or $1.21 a share, a year earlier. Per-share earnings from continuing operations were $1.35 versus $1.14.

Revenue increased 3.7% to $1.9 billion. Analysts polled by Thomson Reuters most recently forecast earnings of $1.24 a share on revenue of $1.86 billion.

Gross margin widened to 52.9% from 50.8%.

Becton Dickinson's sales grew 3% in the U.S. and 4.3% internationally. The company's medical unit, its largest by revenue, reported sales rose 3.5%. The diagnostics business posted revenue growth 5%, while bioscience revenue was up 1.7%.

Shares closed Monday at $85.16 and were inactive premarket. The stock has risen 11% in the past three months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Becton, Dickinson and Co., Corning Incorporated
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BECTON DICKINSON AND CO
12:58p BECTON DICKINSON AND : Alabama's execution drugs may be close to expiring
06/24 BECTON DICKINSON AND : Free Clinic upgrades with no-cost laboratory
06/23 BECTON DICKINSON AND : Free Clinic upgrades with no-cost laboratory
06/22 BECTON DICKINSON AND : Patent Issued for Infusion Reservoir with Push-On Connect..
06/22 BECTON DICKINSON AND : BD Receives FDA 510k Clearance for New Line of Customizab..
06/22 BECTON DICKINSON AND CO : Corporate News Blog - BD Receives FDA 501(k) Clearance..
06/20 BECTON DICKINSON AND : BD Receives FDA 510k Clearance for New Line of Customizab..
06/20 BECTON DICKINSON AND : BD Receives FDA 510(k) Clearance for New Line of Customiz..
06/15 BECTON DICKINSON AND : Researchers Submit Patent Application, "Short Injection L..
06/15 BECTON DICKINSON AND : BD Receives FDA 510K Clearance for Molecular Test for Har..
More news
Sector news : Medical Supplies
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/16 Earnings drag on European shares, though Vodafone lifts telcos
05/09 French outbound M&A driven to decade high by big deals
05/06DJProfits Jump, Spending Lags -- WSJ
More sector news : Medical Supplies
News from SeekingAlpha
06/22 BECTON, DICKINSON : A Quality Dividend Aristocrat With Double-Digit Payout Growt..
06/20 BECTON DICKINSON : Dividend Jewel - In The Service Of Medicine
06/16 SNIPPET ROUNDUP : Novartis Enters Advair Generic Race, Biogen Dealt CFO Blow
06/15 VIG Never Looked So Dividend-y
06/13 RISK ARBITRAGE TODAY POLL : Tech Wreck Or Buying Opportunity
Advertisement
Financials ($)
Sales 2017 12 052 M
EBIT 2017 2 772 M
Net income 2017 1 618 M
Debt 2017 8 955 M
Yield 2017 1,50%
P/E ratio 2017 24,95
P/E ratio 2018 21,82
EV / Sales 2017 4,40x
EV / Sales 2018 4,10x
Capitalization 44 119 M
More Financials
Chart BECTON DICKINSON AND CO
Duration : Period :
Becton Dickinson and Co Technical Analysis Chart | BDX | US0758871091 | 4-Traders
Full-screen chart
Technical analysis trends BECTON DICKINSON ...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 200 $
Spread / Average Target 2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent A. Forlenza Chairman & Chief Executive Officer
Thomas Polen President
Christopher R. Reidy EVP, Chief Financial & Administrative Officer
Ellen R. Strahlman Chief Medical Officer, EVP-Research & Development
Bertram L. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BECTON DICKINSON AND C..17.88%44 119
TELEFLEX INCORPORATED27.90%9 271
SHANDONG WEIGAO GROUP ..13.20%3 380
HARTALEGA HOLDINGS BER..--.--%2 681
TOP GLOVE CORPORATION ..--.--%1 659
HOGY MEDICAL CO., LTD.7.77%1 141
More Results